Open Clinical Studies
Our active clinical research studies are a driving force behind the world-class care provided at Ward 86 and the Infectious Diseases (ID) Clinic, advancing treatment, prevention, and understanding of HIV and infectious diseases.
Most of our study visits are conducted at Zuckerberg San Francisco General, in the Community Clinical Research Center (CCRC) at Pride Hall, a new facility dedicated to clinical research.
Explore current studies below to learn more about eligibility and how to participate:
COVID-19
Long-term Impact of Infection with Novel Coronavirus (LIINC)
The Long-term Impact of Infection with Novel Coronavirus (LIINC) study is a collaboration of University of California researchers looking for adult volunteers who have had a confirmed or suspected COVID-19 infection. Our team is working to understand the changes that happen after recovery from the virus.
LIINC is a team effort that connects researchers across UCSF and the United States with the goal of understanding the immune response to the virus and how it affects a person's body during recovery.
For information on enrollment, visit the LIINC website.
Studies for People Living with HIV
Effect of Methamphetamine on Residual Latent HIV Disease (EMRLHD) Cohort Study
The EMRLHD Cohort Study is based in UCSF Pride Hall at Zuckerberg San Francisco General. Our team is looking at the relationship between HIV, the immune system, and methamphetamine (MA) use.
EMRLHD is looking to enroll participants living with HIV on antiretrovirals who have current meth use or no current meth use.
For information on enrollment, contact the study team at [email protected] or (415) 340-2303.
Study of the Consequences of the Protease Inhibitor Era (SCOPE) Study
The SCOPE Study is a long-term, observational research project at Zuckerberg San Francisco General focused on people living with and without HIV.
Its goal is to bridge clinical care and laboratory research by maintaining a diverse cohort and an extensive repository of biological specimens and clinical data. The team collaborates broadly with academic and industry partners to help advance the search for an HIV cure.
The study supports groundbreaking research, including early-phase clinical trials aimed at reducing HIV-related inflammation and the viral reservoir. SCOPE data and samples are used to study:
- Disease progression
- Natural viral control
- Immune responses
- Drug resistance
- Transmission factors
For information on enrollment, visit the SCOPE Study website or call (415) 476-4082 x140.
A5321 – Observational Study for People with New Confirmed or Suspected HIV Infection After Use of Injectable Cabotegravir for HIV PrEP (Group 6)
Basic Eligibility Criteria
Individuals who have used injectable cabotegravir for PrEP within 90 days of a blood sample concerning for possible HIV infection. Excludes those with HIV RNA >1000 copies/mL or who are currently on antiretroviral therapy (ART).
Study Design
This observational study aims to characterize the HIV reservoir, inflammatory consequences, and viral evolution after breakthrough infection, including after ART initiation. Participants will also be referred to the SeroPrep Study.
For More Information
To learn more about the study or inquire about enrollment, please visit our program website at hividgm.ucsf.edu/sfidrc, email [email protected], or text/call 415-806-8554.
A5402 – An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons with HIV
Basic Eligibility Criteria
Adults aged 18–70 living with HIV, with a confirmed diagnosis of MDD, stable on ART for ≥3 months, undetectable viral load, not currently on antidepressants, and able to take oral medication. Those who can become pregnant must test negative and use contraception.
Study Design
This study compares pramipexole extended release versus escitalopram for treating MDD and MDD with MND in people with HIV, while also examining impacts on daily functioning.
For More Information
To learn more about the study or inquire about enrollment, please visit our program website at hividgm.ucsf.edu/sfidrc, email [email protected], or text/call 415-806-8554.
A5422 – Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living with HIV-1 on Suppressive Antiretroviral Therapy
Basic Eligibility Criteria
Adults aged 18+ living with HIV-1, on stable ART for ≥2 years, with a CD4+ count ≥200, HIV viral load <50 for the past year, no current Hepatitis B or C infection, and using birth control if applicable.
Study Design
Evaluates the safety and immune effects of an investigational HIV vaccine. Participants receive 10 injections (five per arm) over a year. Random assignment gives a 2-in-3 chance of receiving the vaccine and a 1-in-3 chance of placebo.
For More Information
To learn more about the study or inquire about enrollment, please visit our program website at hividgm.ucsf.edu/sfidrc, email [email protected], or text/call 415-806-8554.
A5424 – Menopausal Hormone Therapy for Women Living with HIV (HoT Study)
Basic Eligibility Criteria
Individuals assigned female at birth, ages 40–60, in late perimenopause or early postmenopause, living with HIV, on ART for >1 year, not pregnant, and willing to use contraception and complete a daily diary.
Study Design
This two-group study compares hormone replacement therapy (estradiol gel with or without oral progesterone) to placebo in women with HIV.
For More Information
To learn more about the study or inquire about enrollment, please visit our program website at hividgm.ucsf.edu/sfidrc, email [email protected], or text/call 415-806-8554.
GSK 209639 – The Embrace Study - Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Adults Living with HIV
Basic Eligibility Criteria
Adults 18-70 years of age, diagnosed with HIV-1, taking standard HIV treatment for at least 6 months, and who have had a successful response to treatment.
Study Design
The EMBRACE Study is testing a study drug combination to see whether it can maintain a low amount of HIV virus inside the body without daily dosing.
For More Information
To learn more about the study or inquire about enrollment, please visit our program website at hividgm.ucsf.edu/sfidrc, email [email protected], or text/call 415-806-8554.
Merck 060 – Phase 2 Study of ISL+ULO Once Weekly in Virologically Suppressed Adults With HIV-1
Basic Eligibility Criteria
Adults living with HIV-1, currently taking BIC/FTC/TAF with good viral control for ≥6 months, and no history of treatment failure. Retesting allowed within 45 days if screening values are borderline.
Study Design
Compares once-weekly ISL+ULO treatment to daily BIC/FTC/TAF by evaluating HIV viral control after 24 weeks.
For More Information
To learn more about the study or inquire about enrollment, please visit our program website at hividgm.ucsf.edu/sfidrc, email [email protected], or text/call 415-806-8554.